![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 31, 21491-21494, July 30, 1999
§ and
From the
Department of Biochemistry and Molecular
Biology, University of Kansas Medical Center, Kansas City, Kansas
66160 and the ¶ Department of Biochemistry and Molecular Biology,
University of Miami, School of Medicine, Miami, Florida 33101
The timely breakdown of extracellular matrix
(ECM)1 is essential for
embryonic development, morphogenesis, reproduction, and tissue
resorption and remodeling. The matrix metalloproteinases (MMPs), also
called matrixins, are thought to play a central role in these
processes. The expression of most matrixins is transcriptionally regulated by growth factors, hormones, cytokines, and cellular transformation (1, 2). The proteolytic activities of MMPs are precisely
controlled during activation from their precursors and inhibition by
endogenous inhibitors, All matrixins are synthesized as prepro-enzymes and secreted as
inactive pro-MMPs in most cases. The primary structures of 20 vertebrate matrixins comprise several domain motifs, as illustrated in
Fig. 1; the domain composition for each
MMP is listed in Table I.
![]()
INTRODUCTION
TOP
INTRODUCTION
Domain Structure and Function
Regulation of Matrixin Gene...
Activation of Pro-matrixins:...
Inhibition Mechanism of TIMPs
TIMPs Are Multifunctional...
Biological and Pathological...
Future Prospects
REFERENCES
-macroglobulins, and tissue inhibitors of
metalloproteinases (TIMPs). Table I lists currently known vertebrate matrixins. In addition, non-vertebrate members have been identified in sea urchins (3), Caenorhabditis elegans (4), soybean (5), and Arabidopsis thaliana (6). Most of these MMPs are the subject of individual chapters in the Handbook of Proteolytic Enzymes (7). This minireview focuses on recent progress in regulation of matrixin activities and their biological and pathological implications.
Vertebrate members of the matrixin family
![]()
Domain Structure and Function
TOP
INTRODUCTION
Domain Structure and Function
Regulation of Matrixin Gene...
Activation of Pro-matrixins:...
Inhibition Mechanism of TIMPs
TIMPs Are Multifunctional...
Biological and Pathological...
Future Prospects
REFERENCES

View larger version (39K):
[in a new window]
Fig. 1.
Domain arrangements of vertebrate
matrixins.
The propeptide domain (about 80 amino acids) has a conserved unique PRCG(V/N)PD sequence. The Cys within this sequence (the "cysteine switch") ligates the catalytic zinc to maintain the latency of pro-MMPs (8, 9). This sequence is missing in MMP-23 (10). Stromelysin 3 (MMP-11), MT-MMPs, Xenopus MMP, and MMP-23 have a proprotein processing sequence RX(K/R)R at the C-terminal end of the propeptide, and MMP-11 (11) and MMP-14 (12) were shown to be activated intracellularly by furin.
The catalytic domain (about 170 amino acids) contains a zinc binding
motif HEXXHXXGXXH and a conserved
methionine, which forms a unique "Met-turn" structure (13). This
domain consists of a five-stranded
-sheet, three
-helices, and
bridging loops (14). These backbone structures including the
"Met-turn" are similar to those of the members from other
metalloproteinase families, i.e. astacins, reprolysins
(ADAMs), and serralysins; these four families constitute the
"metzincins" (13). The catalytic domains of matrixins have an
additional structural zinc ion and 2-3 calcium ions, which are
required for the stability and the expression of enzymic activity.
MMP-2 and MMP-9 have three repeats of fibronectin-type II domain
inserted in the catalytic domain. These repeats interact with collagens
and gelatins (15, 16).
The C-terminal hemopexin-like domain (about 210 amino acids) has an
ellipsoidal disk shape with a four bladed
-propeller structure; each
blade consists of four antiparallel
-strands and an
-helix (17).
The hemopexin domain is an absolute requirement for collagenases to
cleave triple helical interstitial collagens (18), although the
catalytic domains alone retain proteolytic activity toward other
substrates (19). The hemopexin domain of MMP-2 is also required for the
cell surface activation of pro-MMP-2 by MT1-MMP (20, 21). The function
of the proline-rich linker peptide that connects the catalytic and the
hemopexin domains is not known, although its interaction with triple
helical collagen is hypothesized based on molecular modeling (22).
MMP-23 has cysteine-rich, proline-rich, and IL-1 receptor-like regions
instead of the hemopexin domain (10). A transmembrane domain is found in the MT-MMPs, which anchors those enzymes to the cell surface.
| |
Regulation of Matrixin Gene Expression |
|---|
|
|
|---|
One of the striking features of the matrixins is that many of
those genes are "inducible." The effectors include growth factors, cytokines, chemical agents (e.g. phorbol esters, actin
stress fiber-disrupting drugs), physical stress, and oncogenic cellular transformation, etc., and the enhanced MMP gene expression may be
down-regulated by suppressive factors (e.g. transforming
growth factor
, retinoic acids, glucocorticoids) (1). Induction and suppression through the promoter regions of matrixin genes have recently been reviewed by Fini et al. (2).
Recent studies emphasize not only soluble factors but also cell-matrix
and cell-cell interactions as keys in gene expression of matrixins.
Examples are: induction of MMP-1, -2, and -3 in fibroblasts by EMMPRIN
(M6 antigen or basigin), a member of the immunoglobulin family
expressed on tumor cell surface (23); induction of MMP-9 in T lymphoma
cells through leukocyte function-associated antigen-1
(LFA-1)-intercellular adhesion molecule-1 (ICAM-1)-mediated cell
adhesion (24); induction of MMP-2 in T cells through very late antigen
4 (VLA-4)-vascular cell adhesion molecule-1 (VCAM-1)-mediated adhesion
to endothelial cells (25); MMP-9 expression in monocytes by the
activated T cells through gp39-CD40 interaction (26); and
5
1 integrin-fibronectin interaction for
MMP-9 expression during macrophage differentiation (27). Endothelial
cells (28, 29), fibroblasts (30), and neoplastic cells (31) cultured in
type I collagen gel express MT1-MMP, which appears to be mediated by
2
1 integrin (30).
Certain signaling pathways lead to expression of a particular MMP gene.
Addition of soluble antibody to
5
1
integrin causes disruption of the actin cytoskeleton and an increased
expression of MMP-1 in rabbit synovial fibroblasts (32). This is
because of activation of the GTP-binding protein Rac1, which generated reactive oxygen species and induced activation of NF-
B (33). This
leads to induction of IL-1
, an autocrine inducer of MMP-1 expression. This pathway is distinct from
integrin-dependent spreading, which leads to MMP-1
expression mediated through AP-1 and PEA3-binding sites (34) but does
not require the Rho-family GTPase pathway (33).
Inflammatory cytokines, TNF-
and IL-1, trigger the ceramide
signaling pathways (35). The ceramide-dependent expression of MMP-1 in human skin fibroblast is mediated by three distinct MAP
kinase pathways, i.e. ERK1/2, stress-activated protein
kinase (SAPK)/JNK, and p38 (36). The maximal induction of MMP-1 gene expression in human astrocytes by oncostatin M is
Raf1-dependent and requires cross-talk between the Janus
kinase (JAK)-signal transducer and activator of transcription (STAT)
and MAP kinase pathways (37).
Ultraviolet B irradiation up-regulates MMP-1, MMP-3, and MMP-9
expression in human dermal fibroblasts (38). Brenneisen et al. (39) reported that this was mediated by the activation of stress-activated protein kinase JNK-2 through the generation of reactive oxygen species and lipid peroxidation by the ion-driven Fenton
reaction. The exposure of human skin to ultraviolet B in vivo activates epidermal growth factor receptor and the
GTP-binding regulatory protein Ras, and stimulates ERK, JNK, and p38
MAP kinase pathways, which phosphorylate and activate c-Jun and ATF-2.
c-Jun and ATF-2 heterodimers in turn bind to the c-Jun promoter and up-regulate c-Jun, which together with c-Fos increased levels of AP-1
required for MMP transcription (40).
| |
Activation of Pro-matrixins: Cell Surface Activation of Pro-MMP2 |
|---|
|
|
|---|
Apart from a few members activated by furin (see above), most are secreted from the cell as inactive zymogens. Secreted pro-matrixins are activated in vitro by proteinases and by non-proteolytic agents such as SH-reactive agents, mercurial compounds, reactive oxygen, and denaturants. In all cases activation requires the disruption of the Cys-Zn2+ (cysteine switch) interaction, and the removal of the propeptide proceeds often in a stepwise manner (41). In vivo, most pro-matrixins are likely to be activated by tissue or plasma proteinases or opportunistic bacterial proteinases. Using transgenic mice deficient in uPA, Carmeliet et al. (42) have suggested that the uPA/plasmin system is a pathophysiologically significant activator of pro-matrixins. The activation of pro-MMP-2, on the other hand, is thought to take place primarily on the cell surface.
In 1994, Sato et al. (43) cloned the first membrane-type MMP (MT1-MMP) and demonstrated it to be an activator of pro-MMP-2. Recent studies propose that this activation process requires both active MT1-MMP and the TIMP-2-bound MT1-MMP (21, 44, 45).The TIMP-2 in the latter complex binds, through its C-terminal domain, to the hemopexin domain of pro-MMP-2, which is assumed to localize the zymogen close to the active MT1-MMP (44). Although the major pro-MMP-2 activation pathway appears to be through MT-MMPs, Mazzieri et al. (46) reported that surface-bound pro-MMP-2 also can be activated by the cell surface-associated uPA/plasmin system, whereas soluble plasmin degrades it.
The expression of MT1-MMP and activation of pro-MMP-2 in tumor
cells occur in specialized membrane extensions, invadopodia (47). This
focal location of MT1-MMP is controlled by the transmembrane and
cytoplasmic domains of MT1-MMP. Hiraoka et al. (48) reported that specific fibrinolysis by the plasma membrane-anchored MT1-MMP in
endothelial cells is critical for neovascularization. MMP-2 may also be
localized on the cell surface of angiogenic endothelial cells and
melanoma cells by binding to
v
3 integrin
(49). This interaction is inhibited by a RGD peptide and an excess
C-terminal hemopexin domain of MMP-2, which prevents invasive behavior
of new blood vessels (50). In contrast, binding of pro-MMP-2 to mouse
melanoma cells was not inhibited by the RGDS peptide (51), suggesting
that the modes of MMP-2 binding to the cell surface may vary. Those
studies, nonetheless, emphasize that membrane-bound proteinases such as
MT1-MMP and MMP-2 play an important role in angiogenesis and tumor cell invasion.
| |
Inhibition Mechanism of TIMPs |
|---|
|
|
|---|
TIMPs (21-30 kDa) are the major endogenous regulators of MMP
activities in the tissue, and four homologous TIMPs (TIMPs-1 to -4)
have been identified to date (52). The crystal structure of the complex
formed between TIMP-1 and the catalytic domain of MMP-3 was determined
by Gomis-Rüth et al. (53). The critical residues
involved in MMP inhibition are located around the disulfide bond
between Cys1 and Cys70 (Fig.
2). The N-terminal
-amino and carbonyl
groups of Cys1 bidentately coordinate the catalytic
Zn2+. The N-terminal segment
Cys1-Thr-Cys-Val-Pro5 binds to the active site
cleft subsite S1 to S4' of the enzyme like the substrate, whereas
Ser68 and Val69 in the connecting loop between
strand C and strand D are arranged in an orientation nearly opposite to
that of the P3-P2 segment of a substrate. The side chain of
Thr2 extends into the large S1' specificity pocket of
MMP-3. TIMP-2 binds to matrixins in a similar manner but has a longer
strand A-strand B hairpin loop (54). The high resolution NMR structure of N-TIMP-2 (55) and the crystal structure of free TIMP-2 (56) were
also reported. Proteinase binding causes an internal rotation between
the N-terminal and the C-terminal domains of ~13° and other local
conformational changes, especially in the AB
-hairpin loop in TIMP-2
(56). MMP-3 contact sites in N-TIMP-2 (55) and N-TIMP-1 contact sites
in MMP-3 (57) were also mapped by NMR.
|
| |
TIMPs Are Multifunctional Proteins |
|---|
|
|
|---|
It is widely appreciated that TIMPs inhibit cell invasion in vitro, tumorigenesis, metastasis in vivo, and angiogenesis (52). TIMPs exhibit additional biological functions. TIMP-1 and TIMP-2 have mitogenic activities on a number of cell types, whereas overexpression of these inhibitors reduces tumor cell growth (52), and TIMP-2, but not TIMP-1, inhibits basic fibroblast growth factor-induced human endothelial cell growth (58). These biological activities of TIMPs are independent of MMP-inhibitory activities (59, 60). The TIMP-1-procathepsin L complex was reported to stimulate steroidogenesis of rat testis and ovary in vitro (61), but TIMP-1-deficient mice gave little evidence for regulation of steroidogenesis in vivo (62). TIMP-1 also stimulates fibroblasts to produce MMP-1 (63). Recent studies of Zhao et al. (64) demonstrated TIMP-1 accumulates in the nuclei of human fibroblasts in a cell cycle-dependent manner (maximal at the S phase), suggestive of its participation in cell growth.
More recently, TIMP-3 was shown to induce apoptosis of human colon
carcinoma cells (65) and melanoma cells (66). This is probably because
of stabilization of TNF-
receptors (65); TIMP-3 inhibits
TNF-
-converting enzyme (67) and IL-6 receptor shedding (68).
Overexpression of TIMP-3 in rat vascular smooth muscle cells also
promoted apoptosis, but this effect was independent of MMP inhibition
(69). Similar independence is found when TIMP-1 suppresses B cell
apoptosis induced by CD95-dependent and -independent (cold
shock, serum deprivation, and
-radiation) pathways (70).
TIMP-3 binds to extracellular matrix (71) through the C-terminal domain
of the inhibitor (72). A single mutation in the C-terminal domain
(S156C, G166C, G167C, Y168C, or S181C) is associated with Sorsby's
fundus dystrophy, an autosomal dominant macular disorder that causes
irreversible loss of vision with onset in the third and fourth decade
(73). TIMPs are therefore important regulators not only in matrix
turnover but also in cellular activities.
| |
Biological and Pathological Roles of Matrixins |
|---|
|
|
|---|
Matrixins participate in many normal biological processes
(e.g. embryonic development, blastocyst implantation, organ
morphogenesis, nerve growth, ovulation, cervical dilatation, postpartum
uterine involution, endometrial cycling, hair follicle cycling, bone
remodeling, wound healing, angiogenesis, apoptosis, etc.) and
pathological processes (e.g. arthritis, cancer,
cardiovascular disease, nephritis, neurological disease, breakdown of
blood brain barrier, periodontal disease, skin ulceration, gastric
ulcer, corneal ulceration, liver fibrosis, emphysema, fibrotic lung
disease, etc.) (74). Although the main function of matrixins is removal
of ECM during tissue resorption and progression of many diseases, it is
notable that MMPs also alter biological functions of ECM macromolecules
by specific proteolysis. For example, MMP-2 released by growth cones promotes neurite outgrowth by inactivating neurite-inhibitory chondroitin sulfate proteoglycans, thereby unmasking the
neurite-promoting activity of laminin (75). Specific cleavage of the
Ala586-Leu587 bond in the
2 chain of laminin
5 by MMP-2 induces migration of normal breast epithelial cells by
exposing a cryptic promigratory site on laminin 5 (76). The cleaved
form of laminin 5 was found in tumors and in tissues undergoing
remodeling but not in quiescent tissues (76). Amnion epithelial cells
undergo apoptotic cell death before the onset of labor, which is
closely associated with degradation of type I collagen by collagenase
(most likely MMP-13) (77). Cleavage of type I collagen by MMP-1 and by
MMP-13 initiates keratinocyte migration during reepithelialization (78)
and osteoclast activation (79), respectively.
Further insights into biological and pathological functions of
matrixins have been provided by the use of transgenic animals and gene
transfer techniques (80). The expression of MMP-9 in trophoblast giant
cells appears to be critical during mouse blastocyst outgrowth and in
early implantation stages in vivo (81, 82) and in later
embryonic skeletal tissue development (83). Vu et al. (84)
reported that MMP-9-deficient (MMP-9
/
) mice exhibited
no obvious phenotypic defects. However, these mice exhibited a delayed
long bone growth associated with an abnormally thickened growth plate,
which was accompanied by delayed apoptosis of hypertrophic
chondrocytes, vascularization, and ossification. This abnormality was
detected only during development, and normal appearance of bone was
seen by 8 weeks of age; probably the deficiency was compensated by
other MMPs. MMP-9
/
mice are resistant to subepidermal
blistering in experimental bullous pemphigoid, an autoimmune blistering
disease, due to the lack of MMP-9 in neutrophils (85).
Mice deficient in MMP-12 (metalloelastase), in contrast to the
wild-type, did not develop emphysema in response to long term exposure
to cigarette smoke (86). MMP-12
/
macrophages are unable
to penetrate basement membrane in vitro and in
vivo (87).
The matrixins are considered to participate in dissemination of cancer
cells by breaking down ECM, but they are also important in creating an
environment that supports the initiation and maintenance of growth of
primary and metastatic tumors (88). Mice with adenomatous polyposis
coli (Apc) gene mutation develop spontaneous intestinal tumors, but such mice deficient in MMP-7 showed significantly reduced
tumor multiplicity and growth (89). MMP-11-deficient mice also showed
reduced chemically induced tumorigenesis (90). Those effects may be
related to proteolytic release of growth factors and/or alteration
of cellular environments.
| |
Future Prospects |
|---|
|
|
|---|
With a wealth of information provided in this field over the last
few years we have begun to understand the significance of matrixins in
biology and pathology. The actions of matrixins in vivo are
complex and diverse; they are not restricted to simple breakdown of
ECM, but they may reveal cryptic biological functions of ECM
macromolecules. Both concepts need to be taken into consideration for
our understanding of the timely alteration of cellular environments required in normal development and morphogenesis. We also anticipate the discovery of many more new MMPs, which will introduce further complexity in tissue matrix catabolism. Such discovery will, however, help us reveal more precise mechanisms of tissue matrix turnover. Detailed structural and functional analyses of MMPs led to the development of numerous potent synthetic inhibitors of matrixins, and
some are in clinical trials to treat patients with cancer, arthritis,
periodontal disease, and corneal ulceration. Such agents may be of
great therapeutic value, but concerns remain about the consequences of
inhibiting biologically functioning matrixins and related ADAMs.
Alternative approaches may be tissue-targeted gene therapy with TIMPs
or TIMP variants that selectively inhibit specific metalloproteinases.
The further gain of knowledge about the mechanisms of
cell/tissue-specific regulation of MMP gene expression and their signal
transduction pathways may also lead to the rational design of
inhibitors that perturb the production of MMPs in a particular cell
type without affecting other cells. Such agents will be of great value
not only for understanding of the basic biology of matrix and its
turnover but also for intervention of diseases resulting from aberrant
ECM degradation.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. Ken-ichi Shimokawa for drawing the domain diagram and Dr. Deendayal Dinakarpandian for preparation of the ribbon diagram of the TIMP-1-MMP-3 complex.
| |
FOOTNOTES |
|---|
* This minireview will be reprinted in the 1999 Minireview Compendium, which will be available in December, 1999. This is the third article of four in the "Proteases in Cellular Regulation Minireview Series." This work was supported by National Institutes of Health Grants AR39189 and AR40994 (to H. N.) and AR16940 (to J. F. W.).
§ To whom correspondence should be addressed: Dept. of Biochemistry and Molecular Biology, University of Kansas Medical Center, 3901 Rainbow Blvd., Kansas City, KS 66160. Tel.: 913-588-7079; Fax: 913-588-7111; E-mail: hnagase@kumc.edu.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
ECM, extracellular
matrix;
AP-1, activator protein 1;
ATF-2, activating transcription
factor 2;
ERK1/2, extracellular signal-regulated kinase 1/2;
IL-1, interleukin 1;
JNK, Jun N-terminal kinase;
MAP, mitogen-activated
protein;
MMP, matrix metalloproteinase;
MT-MMP, membrane-type matrix
metalloproteinase;
N-TIMP, N-terminal domain of tissue inhibitor of
metalloproteinases;
TIMP, tissue inhibitor of metalloproteinases;
TNF-
, tumor necrosis factor
;
uPA, urokinase-type plasminogen
activator.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Nagase, H. (1996) in Zinc Metalloproteases in Health and Disease (Hooper, N. M., ed) , pp. 153-204, Taylor & Francis, London |
| 2. | Fini, M. E., Cook, J. R., Mohan, R., and Brinckerhoft, C. E. (1998) in Matrix Metalloproteinases (Parks, W. C. , and Mecham, R. P., eds) , pp. 299-356, Academic Press, San Diego |
| 3. | Lepage, T., and Gache, C. (1990) EMBO J. 9, 3003-3012[Medline] [Order article via Infotrieve] |
| 4. | Wada, K., Sato, H., Kinoh, H., Kajita, M., Yamamoto, H., and Seiki, M. (1998) Gene (Amst.) 211, 57-62[CrossRef][Medline] [Order article via Infotrieve] |
| 5. | Pak, J. H., Liu, C. Y., Huangpu, J., and Graham, J. S. (1997) FEBS Lett. 404, 283-288[CrossRef][Medline] [Order article via Infotrieve] |
| 6. |
Massova, I.,
Kotra, L. P.,
Fridman, R.,
and Mobashery, S.
(1998)
FASEB J.
12,
1075-1095 |
| 7. | Barrett, A. J., Rawlings, N. D., and Woessner, J. F. (1998) Handbook of Proteolytic Enzymes , Academic Press, London |
| 8. |
Van Wart, H. E.,
and Birkedal-Hansen, H.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
5578-5582 |
| 9. | Becker, J. W., Marcy, A. I., Rokosz, L. L., Axel, M. G., Burbaum, J. J., Fitzgerald, P. M., Cameron, P. M., Esser, C. K., Hagmann, W. K., Hermes, J. D., and Springer, J. P. (1995) Protein Sci. 4, 1966-1976[Abstract] |
| 10. | Gururajan, R., Grenet, J., Lahti, J. M., and Kidd, V. J. (1998) Genomics 52, 101-106[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Pei, D., and Weiss, S. J. (1995) Nature 375, 244-247[CrossRef][Medline] [Order article via Infotrieve] |
| 12. |
Pei, D.,
and Weiss, S. J.
(1996)
J. Biol. Chem.
271,
9135-9140 |
| 13. | Bode, W., Gomis-Rüth, F. X., and Stöcker, W. (1993) FEBS Lett. 331, 134-140[CrossRef][Medline] [Order article via Infotrieve] |
| 14. | Dhanaraj, V., Ye, Q. Z., Johnson, L. L., Hupe, D. J., Ortwine, D. F., Dunbar, J. B., Jr., Rubin, J. R., Pavlovsky, A., Humblet, C., and Blundell, T. L. (1996) Structure 4, 375-386[Medline] [Order article via Infotrieve] |
| 15. | Allan, J. A., Docherty, A. J. P., Barker, P. J., Huskisson, N. S., Reynolds, J. J., and Murphy, G. (1995) Biochem. J. 309, 299-306 |
| 16. |
Steffensen, B.,
Wallon, U. M.,
and Overall, C. M.
(1995)
J. Biol. Chem.
270,
11555-11566 |
| 17. | Gomis-Rüth, F. X., Gohlke, U., Betz, M., Knäuper, V., Murphy, G., López-Otín, C., and Bode, W. (1996) J. Mol. Biol. 264, 556-566[CrossRef][Medline] [Order article via Infotrieve] |
| 18. | Bode, W. (1995) Structure 3, 527-530[Medline] [Order article via Infotrieve] |
| 19. | Clark, I. M., and Cawston, T. E. (1989) Biochem. J. 263, 201-206[Medline] [Order article via Infotrieve] |
| 20. | Murphy, G., Willenbrock, F., Ward, R. V., Cockett, M. I., Eaton, D., and Docherty, A. J. P. (1992) Biochem. J. 283, 637-641 |
| 21. |
Strongin, A. Y.,
Collier, I.,
Bannikov, G.,
Marmer, B. L.,
Grant, G. A.,
and Goldberg, G. I.
(1995)
J. Biol. Chem.
270,
5331-5338 |
| 22. | de Souza, S. J., Pereira, H. M., Jacchieri, S., and Brentani, R. R. (1996) FASEB J. 10, 927-930[Abstract] |
| 23. |
Guo, H.,
Zucker, S.,
Gordon, M. K.,
Toole, B. P.,
and Biswas, C.
(1997)
J. Biol. Chem.
272,
24-27 |
| 24. |
Aoudjit, F.,
Potworowski, E. F.,
and St-Pierre, Y.
(1998)
J. Immunol.
160,
2967-2973 |
| 25. |
Romanic, A. M.,
and Madri, J. A.
(1994)
J. Cell Biol.
125,
1165-1178 |
| 26. | Malik, N., Greenfield, B. W., Wahl, A. F., and Kiener, P. A. (1996) J. Immunol. 156, 3952-3960[Abstract] |
| 27. |
Xie, B.,
Laouar, A.,
and Huberman, E.
(1998)
J. Biol. Chem.
273,
11576-11582 |
| 28. |
Kadono, Y.,
Okada, Y.,
Namiki, M.,
Seiki, M.,
and Sato, H.
(1998)
Cancer Res.
58,
2240-2244 |
| 29. |
Haas, T. L.,
Davis, S. J.,
and Madri, J. A.
(1998)
J. Biol. Chem.
273,
3604-3610 |
| 30. | Seltzer, J. L., Lee, A. Y., Akers, K. T., Sudbeck, B., Southon, E. A., Wayner, E. A., and Eisen, A. Z. (1994) Exp. Cell Res. 213, 365-374[CrossRef][Medline] [Order article via Infotrieve] |
| 31. | Gilles, C., Polette, M., Seiki, M., Birembaut, P., and Thompson, E. W. (1997) Lab. Invest. 76, 651-660[Medline] [Order article via Infotrieve] |
| 32. |
Werb, Z.,
Tremble, P. M.,
Behrendtsen, O.,
Crowley, E.,
and Damsky, C. H.
(1989)
J. Cell Biol.
109,
877-889 |
| 33. |
Kheradmand, F.,
Werner, E.,
Tremble, P.,
Symons, M.,
and Werb, Z.
(1998)
Science
280,
898-902 |
| 34. |
Tremble, P.,
Damsky, C. H.,
and Werb, Z.
(1995)
J. Cell Biol.
129,
1707-1720 |
| 35. | Spiegel, S., Foster, D., and Kolesnick, R. (1996) Curr. Opin. Cell Biol. 8, 159-167[CrossRef][Medline] [Order article via Infotrieve] |
| 36. |
Reunanen, N.,
Westermarck, J.,
Häkkinen, L.,
Holmström, T. H.,
Elo, I.,
Eriksson, J. E.,
and Kähäri, V. M.
(1998)
J. Biol. Chem.
273,
5137-5145 |
| 37. |
Korzus, E.,
Nagase, H.,
Rydell, R.,
and Travis, J.
(1997)
J. Biol. Chem.
272,
1188-1196 |
| 38. | Fisher, G. J., Datta, S. C., Talwar, H. S., Wang, Z. Q., Varani, J., Kang, S., and Voorhees, J. J. (1996) Nature 379, 335-339[CrossRef][Medline] [Order article via Infotrieve] |
| 39. |
Brenneisen, P.,
Wenk, J.,
Klotz, L. O.,
Wlaschek, M.,
Briviba, K.,
Krieg, T.,
Sies, H.,
and Scharffetter-Kochanek, K.
(1998)
J. Biol. Chem.
273,
5279-5287 |
| 40. |
Fisher, G. J.,
Talwar, H. S.,
Lin, J. Y.,
Lin, P. P.,
McPhillips, F.,
Wang, Z. Q.,
Li, X. Y.,
Wan, Y. S.,
Kang, S. W.,
and Voorhees, J. J.
(1998)
J. Clin. Invest.
101,
1432-1440 |
| 41. | Nagase, H. (1997) Biol. Chem. 378, 151-160 |
| 42. | Carmeliet, P., Moons, L., Lijnen, R., Baes, M., Lemaitre, V., Tipping, P., Drew, A., Eeckhout, Y., Shapiro, S., Lupu, F., and Collen, D. (1997) Nat. Genet. 17, 439-444[CrossRef][Medline] [Order article via Infotrieve] |
| 43. | Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E., and Seiki, M. (1994) Nature 370, 61-65[CrossRef][Medline] [Order article via Infotrieve] |
| 44. |
Butler, G. S.,
Butler, M. J.,
Atkinson, S. J.,
Will, H.,
Tamura, T.,
Vanwestrum, S. S.,
Crabbe, T.,
Clements, J.,
d'Ortho, M. P.,
and Murphy, G.
(1998)
J. Biol. Chem.
273,
871-880 |
| 45. |
Kinoshita, T.,
Sato, H.,
Okada, A.,
Ohuchi, E.,
Imai, K.,
Okada, Y.,
and Seiki, M.
(1998)
J. Biol. Chem.
273,
16098-16103 |
| 46. | Mazzieri, R., Masiero, L., Zanetta, L., Monea, S., Onisto, M., Garbisa, S., and Mignatti, P. (1997) EMBO J. 16, 2319-2332[CrossRef][Medline] [Order article via Infotrieve] |
| 47. |
Nakahara, H.,
Howard, L.,
Thompson, E. W.,
Sato, H.,
Seiki, M.,
Yeh, Y. Y.,
and Chen, W. T.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
7959-7964 |
| 48. | Hiraoka, N., Allen, E., Apel, I. J., Gyetko, M. R., and Weiss, S. J. (1998) Cell 95, 365-377[CrossRef][Medline] [Order article via Infotrieve] |
| 49. | Brooks, P. C., Stromblad, S., Sanders, L. C., von Schalscha, T. L., Aimes, R. T., Stetler-Stevenson, W. G., Quigley, J. P., and Cheresh, D. A. (1996) Cell 85, 683-693[CrossRef][Medline] [Order article via Infotrieve] |
| 50. | Brooks, P. C., Silletti, S., von Schalscha, T. L., Friedlander, M., and Cheresh, D. A. (1998) Cell 92, 391-400[CrossRef][Medline] [Order article via Infotrieve] |
| 51. |
Bafetti, L. M.,
Young, T. N.,
Itoh, Y.,
and Stack, M. S.
(1998)
J. Biol. Chem.
273,
143-149 |
| 52. | Gomez, D. E., Alonso, D. F., Yoshiji, H., and Thorgeirsson, U. P. (1997) Eur. J. Cell Biol. 74, 111-122[Medline] [Order article via Infotrieve] |
| 53. | Gomis-Rüth, F. X., Maskos, K., Betz, M., Bergner, A., Huber, R., Suzuki, K., Yoshida, N., Nagase, H., Brew, K., Bourenkov, G. P., Bartunik, H., and Bode, W. (1997) Nature 389, 77-81[CrossRef][Medline] [Order article via Infotrieve] |
| 54. | Fernandez-Catalan, C., Bode, W., Huber, R., Turk, D., Calvete, J. J., Lichte, A., Tschesche, H., and Maskos, K. (1998) EMBO J. 17, 5238-5248[CrossRef][Medline] [Order article via Infotrieve] |
| 55. |
Muskett, F. W.,
Frenkiel, T. A.,
Feeney, J.,
Freedman, R. B.,
Carr, M. D.,
and Williamson, R. A.
(1998)
J. Biol. Chem.
273,
21736-21743 |
| 56. | Tuuttila, A., Morgunova, E., Bergmann, U., Lindqvist, Y., Maskos, K., Fernandez-Catalan, C., Bode, W., Tryggvason, K., and Schneider, G. (1998) J. Mol. Biol. 284, 1133-1140[CrossRef][Medline] [Order article via Infotrieve] |
| 57. | Arumugam, S., Hemme, C. L., Yoshida, N., Suzuki, K., Nagase, H., Bejanskii, M., Wu, B., and Van Doren, S. R. (1998) Biochemistry 37, 9650-9657[CrossRef][Medline] [Order article via Infotrieve] |
| 58. | Murphy, A. N., Unsworth, E. J., and Stetler-Stevenson, W. G. (1993) J. Cell. Physiol. 157, 351-358[CrossRef][Medline] [Order article via Infotrieve] |
| 59. | Hayakawa, T., Yamashita, K., Ohuchi, E., and Shinagawa, A. (1994) J. Cell Sci. 107, 2373-2379[Abstract] |
| 60. |
Chesler, L.,
Golde, D. W.,
Bersch, N.,
and Johnson, M. D.
(1995)
Blood
86,
4506-4515 |
| 61. |
Boujrad, N.,
Ogwuegbu, S. O.,
Garnier, M.,
Lee, C. H.,
Martin, B. M.,
and Papadopoulos, V.
(1995)
Science
268,
1609-1612 |
| 62. | Nothnick, W. B., Soloway, P., and Curry, T. E. (1997) Biol. Reprod. 56, 1181-1188[Abstract] |
| 63. | Clark, I. M., Powell, L. K., and Cawston, T. E. (1994) Biochem. Biophys. Res. Commun. 203, 874-880[CrossRef][Medline] [Order article via Infotrieve] |
| 64. | Zhao, W. Q., Li, H., Yamashita, K., Guo, X. K., Hoshino, T., Yoshida, S., Shinya, T., and Hayakawa, T. (1998) J. Cell Sci. 111, 1147-1153[Abstract] |
| 65. | Smith, M. R., Kung, H. F., Durum, S. K., Colburn, N. H., and Sun, Y. (1997) Cytokine 9, 770-780[CrossRef][Medline] [Order article via Infotrieve] |
| 66. |
Ahonen, M.,
Baker, A. H.,
and Kähäri, V. M.
(1998)
Cancer Res.
58,
2310-2315 |
| 67. | Amour, A., Slocombe, P. M., Webster, A., Butler, M., Knight, C. G., Smith, B. J., Stephens, P. E., Shelley, C., Hutton, M., Knäuper, V., Docherty, A. J. P., and Murphy, G. (1998) FEBS Lett. 435, 39-44[CrossRef][Medline] [Order article via Infotrieve] |
| 68. | Hargreaves, P. G., Wang, F. F., Antcliff, J., Murphy, G., Lawry, J., Russell, R. G. G., and Croucher, P. I. (1998) Br. J. Haematol. 101, 694-702[CrossRef][Medline] [Order article via Infotrieve] |
| 69. |
Baker, A. H.,
Zaltsman, A. B.,
George, S. J.,
and Newby, A. C.
(1998)
J. Clin. Invest.
101,
1478-1487 |
| 70. |
Guedez, L.,
Stetler-Stevenson, W. G.,
Wolff, L.,
Wang, J.,
Fukushima, P.,
Mansoor, A.,
and Stetler-Stevenson, M.
(1998)
J. Clin. Invest.
102,
2002-2010 |
| 71. |
Pavloff, N.,
Staskus, P. W.,
Kishnani, N. S.,
and Hawkes, S. P.
(1992)
J. Biol. Chem.
267,
17321-17326 |
| 72. |
Langton, K. P.,
Barker, M. D.,
and McKie, N.
(1998)
J. Biol. Chem.
273,
16778-16781 |
| 73. | Felbor, U., and Weber, B. H. (1998) Ophthalmologe 95, 287-290[CrossRef][Medline] [Order article via Infotrieve] |
| 74. | Parks, W. C., and Mecham, R. P. (1998) Matrix Metalloproteinases , Academic Press, San Diego |
| 75. |
Zuo, J.,
Ferguson, T. A.,
Hernandez, Y. J.,
Stetler-Stevenson, W. G.,
and Muir, D.
(1998)
J. Neurosci.
18,
5203-5211 |
| 76. |
Giannelli, G.,
Falkmarzillier, J.,
Schiraldi, O.,
Stetler-Stevenson, W. G.,
and Quaranta, V.
(1997)
Science
277,
225-228 |
| 77. |
Lei, H.,
Furth, E. E.,
Kalluri, R.,
Chiou, T.,
Tilly, K. I.,
Tilly, J. L.,
Elkon, K. B.,
Jeffrey, J. J.,
and Strauss, J. F., III
(1996)
J. Clin. Invest.
98,
1971-1978 |
| 78. |
Pilcher, B. K.,
Dumin, J. A.,
Sudbeck, B. D.,
Krane, S. M.,
Welgus, H. G.,
and Parks, W. C.
(1997)
J. Cell Biol.
137,
1445-1457 |
| 79. |
Holliday, L. S.,
Welgus, H. G.,
Fliszar, C. J.,
Veith, G. M.,
Jeffrey, J. J.,
and Gluck, S. L.
(1997)
J. Biol. Chem.
272,
22053-22058 |
| 80. | Shapiro, S. D. (1998) Curr. Opin. Cell Biol. 10, 602-608[CrossRef][Medline] [Order article via Infotrieve] |
| 81. | Alexander, C. M., Hansell, E. J., Behrendtsen, O., Flannery, M. L., Kishnani, N. S., Hawkes, S. P., and Werb, Z. (1996) Development 122, 1723-1736[Abstract] |
| 82. | Das, S. K., Yano, S., Wang, J., Edwards, D. R., Nagase, H., and Dey, S. K. (1997) Dev. Genet. 21, 44-54[CrossRef][Medline] [Order article via Infotrieve] |
| 83. |
Reponen, P.,
Sahlberg, C.,
Munaut, C.,
Thesleff, I.,
and Tryggvason, K.
(1994)
J. Cell Biol.
124,
1091-1102 |
| 84. | Vu, T. H., Shipley, J. M., Bergers, G., Berger, J. E., Helms, J. A., Hanahan, D., Shapiro, S. D., Senior, R. M., and Werb, Z. (1998) Cell 93, 411-422[CrossRef][Medline] [Order article via Infotrieve] |
| 85. |
Liu, Z.,
Shipley, J. M.,
Vu, T. H.,
Zhou, X. Y.,
Diaz, L. A.,
Werb, Z.,
and Senior, R. M.
(1998)
J. Exp. Med.
188,
475-482 |
| 86. |
Hautamaki, R. D.,
Kobayashi, D. K.,
Senior, R. M.,
and Shapiro, S. D.
(1997)
Science
277,
2002-2004 |
| 87. |
Shipley, J. M.,
Wesselschmidt, R. L.,
Kobayashi, D. K.,
Ley, T. J.,
and Shapiro, S. D.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
3942-3946 |
| 88. |
Chambers, A. F.,
and Matrisian, L. M.
(1997)
J. Natl. Cancer Inst.
89,
1260-1270 |
| 89. |
Wilson, C. L.,
Heppner, K. J.,
Labosky, P. A.,
Hogan, B. L.,
and Matrisian, L. M.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
1402-1407 |
| 90. |
Masson, R.,
Lefebvre, O.,
Noel, A.,
El Fahime, M.,
Chenard, M. P.,
Wendling, C.,
Kebers, F.,
LeMeur, M.,
Dierich, A.,
Foidart, J.-M.,
Basset, P.,
and Rio, M.-C.
(1998)
J. Cell Biol.
140,
1535-1541 |
| 91. | Carson, M. (1997) Methods Enzymol. 277, 493-505 |
This article has been cited by other articles:
![]() |
J Monfort, J-P Pelletier, N Garcia-Giralt, and J Martel-Pelletier Biochemical basis of the effect of chondroitin sulphate on osteoarthritis articular tissues Ann Rheum Dis, June 1, 2008; 67(6): 735 - 740. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Malla, E. Berg, L. Uhlin-Hansen, and J.-O. Winberg Interaction of Pro-matrix Metalloproteinase-9/Proteoglycan Heteromer with Gelatin and Collagen J. Biol. Chem., May 16, 2008; 283(20): 13652 - 13665. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Mitra, M. Goto, J. S. Lee, D. Maldonado, J. M.G. Taylor, Q. Pan, T. E. Carey, C. R. Bradford, M. E. Prince, K. G. Cordell, et al. Rap1GAP Promotes Invasion via Induction of Matrix Metalloproteinase 9 Secretion, Which Is Associated with Poor Survival in Low N-Stage Squamous Cell Carcinoma Cancer Res., May 15, 2008; 68(10): 3959 - 3969. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Rathmell A 50-Year-Old Man With Chronic Low Back Pain JAMA, May 7, 2008; 299(17): 2066 - 2077. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Koyama, H. Naruo, Y. Yoshitomi, S. Munesue, S. Kiyono, Y. Kusano, K. Hashimoto, T. Yokoi, H. Nakanishi, S. Shimizu, et al. Matrix Metalloproteinase-9 Associated with Heparan Sulphate Chains of GPI-Anchored Cell Surface Proteoglycans Mediates Motility of Murine Colon Adenocarcinoma Cells J. Biochem., May 1, 2008; 143(5): 581 - 592. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Pan, C.-H. Wen, and C.-S. Lin Interplay of angiotensin II and angiotensin(1-7) in the regulation of matrix metalloproteinases of human cardiocytes Exp Physiol, May 1, 2008; 93(5): 599 - 612. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Rogliani, M. Mura, M. Assunta Porretta, and C. Saltini Review: New perspectives in the treatment of idiopathic pulmonary fibrosis Therapeutic Advances in Respiratory Disease, April 1, 2008; 2(2): 75 - 93. [Abstract] [PDF] |
||||
![]() |
T. Eguchi, S. Kubota, K. Kawata, Y. Mukudai, J. Uehara, T. Ohgawara, S. Ibaragi, A. Sasaki, T. Kuboki, and M. Takigawa Novel Transcription Factor-Like Function of Human Matrix Metalloproteinase 3 Regulating the CTGF/CCN2 Gene Mol. Cell. Biol., April 1, 2008; 28(7): 2391 - 2413. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Hillegass, C. M. Villano, K. R. Cooper, and L. A. White Glucocorticoids Alter Craniofacial Development and Increase Expression and Activity of Matrix Metalloproteinases in Developing Zebrafish (Danio rerio) Toxicol. Sci., April 1, 2008; 102(2): 413 - 424. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. Berthier, P. R. Wahl, M. L. Hir, H.-P. Marti, U. Wagner, H. Rehrauer, R. P. Wuthrich, and A. L. Serra Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of autosomal dominant polycystic kidney disease Nephrol. Dial. Transplant., March 1, 2008; 23(3): 880 - 889. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gerg, C. Kopitz, S. Schaten, A. Tschukes, C. Kahlert, M. Stangl, C. W. Hann von Weyhern, B. L.D.M. Brucher, D. R. Edwards, K. Brand, et al. Distinct Functionality of Tumor Cell-Derived Gelatinases during Formation of Liver Metastases Mol. Cancer Res., March 1, 2008; 6(3): 341 - 351. [Abstract] [Full Text] |